1Dept. of Biomedical Sciences and Morpho-Functional Imaging, Polyclinic University of Messina, Messina, Italy
2Laboratory of Tissue Engineering and Skin Pathophysiology, Dermatology Institute (IDI IRCCS), Rome, Italy
32nd Dermatology Division, Dermatology Institute (IDI IRCCS), Rome, Italy
Corresponding Author: Dr. Chiara De Luca,PhD, Laboratory of Tissue
Engineering and Skin Pathophysiology, Dermatology Institute (IDI
IRCCS), Via Monti di Creta 104, Rome 00167, Italy,
Tel. +39 06 9112193, fax +39 06 9112192, e.mail email@example.com.
In the environmental sensitivity-related illnesses (SRI) multiple chemical sensitivity (MCS), chronic fatigue syndrome (FCS), fibromyalgia (FM), the search for genetic polymorphisms of phase I/II xenobiotic-metabolizing enzymes as suitable diagnostic biomarkers produced so far inconclusive results, due to patient heterogeneity, geographic/ethnic differences in genetic backgrounds, different methodological approaches. Here, we compared the frequency of gene polymorphisms of selected cytochrome P450 (CYP) metabolizing enzymes, and for the first time of the xenobiotic sensor Aryl hydrocarbon receptor (AHR), in the three cohorts of 145 diagnosed MCS, 94 suspected MCS, 80 FM/FCS patients, vs. 113 healthy controls. Contrary to our previous results on 110 Italian MCS patients, we showed, after careful evaluation of MCS established diagnostic criteria, exclusion of FM and FCS co-morbidities, and with techniques reaching 100% specificity and sensitivity for heterozygous genotypes, significantly different polymorphism distributions in-between patients' groups, and vs. controls, concerning CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2D6*4, CYP2D6*41 allele and heterozygous genotype frequencies, also confirmed
by disease risk Odds Ratios. Results allowed us to propose genotyping for these specific CYP variants, together with the AHR Arg554Lys variant, as reliable, cost-effective genetic parameters to be included in the still undefined biomarkers' panel for laboratory diagnosis of the main types of environmental-borne SRI.